8 28 17 BOT Additions 1000x698px

KGI Adds Kiran Mazumdar-Shaw, Richmond Wolf to Board of Trustees

Keck Graduate Institute, a leader in applied life sciences and pharmacy education, has appointed two members to its Board of Trustees. Kiran Mazumdar-Shaw will begin her first term as a trustee while Richmond Wolf starts his second term.

KGI’s Board of Trustees consists of 26 leaders in the industries of bioscience, healthcare, and education.

Kiran Mazumdar-Shaw is a pioneer of the biotechnology industry in India, and through a growing partnership with KGI, she established Biocon Academy, a Center of Excellence for Advanced Learning in Biosciences, in 2014. The program develops high-quality biotech talent that addresses the needs of the biotechnology sector in India.

Biocon Academy’s flagship certificate program in bioscience, in collaboration with KGI, is an 18-week program. It includes classroom sessions in the areas of drug development, research and development, quality and regulatory affairs, delivered by renowned faculty from KGI, along with experiential learning sessions at Biocon through subject matter experts.

Named among Time magazine’s 100 most influential people in the world, Mazumdar-Shaw is recognized as a thought leader who has built a globally recognized biopharmaceutical enterprise that is committed to innovation and affordability in delivering best-in class therapeutics to patients across the globe.

Mazumdar-Shaw’s commitment to affordable healthcare extends beyond business. Her philanthropic initiatives are directed at making a difference to the lives of marginalized communities. She is making an enduring impact on society through Biocon Foundation’s initiatives in the area of primary healthcare, education, and community development. Technology-enabled smart clinics in rural areas are enabling access to affordable healthcare for communities. Public health initiatives in the area of chronic diseases include preventive screenings for diabetes, oral, cervical, and breast cancer, which help in early diagnosis and treatement.

Richmond Wolf is a partner and investment analyst at Capital World Investors, a division of Capital Research and Management. He covers medical technology and REITs in the U.S.

Dr. Wolf joined Capital in January 2006 and was formerly the assistant vice president for technology transfer at the Caltech, a nonprofit university that also manages the Jet Propulsion Laboratory (JPL) for NASA. He was a co-founder of WebEventBroadcasting and Xen Golf and was previously a member of the board of directors of Alexandria Real Estate Equities, Arxceo, and Micromanipulator. He is also member of the Board of Trustees of Caltech, the board of councilors of the Stevens Institute at USC, and he is chairman of the Ahmanson Lovelace Brain Mapping Medical Research Organization at UCLA.

Dr. Wolf is a graduate of Princeton University cum laude, received a Ph.D. from Caltech, and he is a registered patent agent.